157 related articles for article (PubMed ID: 30178893)
41. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
42. Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
Hall MT; Smith MA; Simms KT; Barnabas R; Murray JM; Canfell K
Int J Cancer; 2021 Jul; 149(2):297-306. PubMed ID: 33634857
[TBL] [Abstract][Full Text] [Related]
43. [Human papillomavirus (HPV) vaccines--a new method for the prevention of cervical cancer].
Friedek DA; Ekiel AM; Martirosian G
Wiad Lek; 2007; 60(1-2):34-8. PubMed ID: 17607966
[TBL] [Abstract][Full Text] [Related]
44. HPV-FASTER: Combined strategies of HPV vaccination and HPV screening towards a one visit for cervical cancer preventive campaigns.
Bosch FX; Robles C
Salud Publica Mex; 2018; 60(6):612-616. PubMed ID: 30699264
[No Abstract] [Full Text] [Related]
45. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.
Ronco G; Dillner J; Elfström KM; Tunesi S; Snijders PJ; Arbyn M; Kitchener H; Segnan N; Gilham C; Giorgi-Rossi P; Berkhof J; Peto J; Meijer CJ;
Lancet; 2014 Feb; 383(9916):524-32. PubMed ID: 24192252
[TBL] [Abstract][Full Text] [Related]
46. Human papillomavirus vaccines versus cervical cancer screening.
Stanley M
Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):388-94. PubMed ID: 18538554
[TBL] [Abstract][Full Text] [Related]
47. Mapping HPV Vaccination and Cervical Cancer Screening Practice in the Pacific Region-Strengthening National and Regional Cervical Cancer Prevention.
Obel J; McKenzie J; Buenconsejo-Lum LE; Durand AM; Ekeroma A; Souares Y; Hoy D; Baravilala W; Garland SM; Kjaer SK; Roth A
Asian Pac J Cancer Prev; 2015; 16(8):3435-42. PubMed ID: 25921158
[TBL] [Abstract][Full Text] [Related]
48. Low rates of HPV vaccination and cervical cancer screening: Challenges and opportunities in the context of the COVID-19 pandemic.
Smith DL; Perkins RB
Prev Med; 2022 Jun; 159():107070. PubMed ID: 35461955
[TBL] [Abstract][Full Text] [Related]
49. Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: Example from New Zealand.
Smith MA; Hall M; Lew JB; Canfell K
Vaccine; 2018 Oct; 36(42):6314-6324. PubMed ID: 30224201
[TBL] [Abstract][Full Text] [Related]
50. Does the HPV vaccination programme have implications for cervical screening programmes in the UK?
Beer H; Hibbitts S; Brophy S; Rahman MA; Waller J; Paranjothy S
Vaccine; 2014 Apr; 32(16):1828-33. PubMed ID: 24530938
[TBL] [Abstract][Full Text] [Related]
51. Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis.
Burger EA; de Kok IMCM; Groene E; Killen J; Canfell K; Kulasingam S; Kuntz KM; Matthijsse S; Regan C; Simms KT; Smith MA; Sy S; Alarid-Escudero F; Vaidyanathan V; van Ballegooijen M; Kim JJ
J Natl Cancer Inst; 2020 Sep; 112(9):955-963. PubMed ID: 31821501
[TBL] [Abstract][Full Text] [Related]
52. Cervical cancer screening rate differs by HPV vaccination status: An interim analysis.
Taniguchi M; Ueda Y; Yagi A; Ikeda S; Endo M; Tomimatsu T; Nakayama T; Sekine M; Enomoto T; Kimura T
Vaccine; 2019 Jul; 37(32):4424-4426. PubMed ID: 31272873
[TBL] [Abstract][Full Text] [Related]
53. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean.
Franco EL; Tsu V; Herrero R; Lazcano-Ponce E; Hildesheim A; Muñoz N; Murillo R; Sánchez GI; Andrus JK
Vaccine; 2008 Aug; 26 Suppl 11():L88-95. PubMed ID: 18945406
[TBL] [Abstract][Full Text] [Related]
54. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
55. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
[TBL] [Abstract][Full Text] [Related]
56. [Screening and vaccination: two synergic tools for the prevention of cervical cancer].
Zaratti L; Senatore S; Franco E
Ig Sanita Pubbl; 2007; 63(4):449-57. PubMed ID: 17912281
[TBL] [Abstract][Full Text] [Related]
57. Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
Konno R; Shin HR; Kim YT; Song YS; Sasagawa T; Inoue M; Park JS
Vaccine; 2008 Aug; 26 Suppl 12():M30-42. PubMed ID: 18945412
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.
Usher C; Tilson L; Olsen J; Jepsen M; Walsh C; Barry M
Vaccine; 2008 Oct; 26(44):5654-61. PubMed ID: 18723068
[TBL] [Abstract][Full Text] [Related]
59. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
[TBL] [Abstract][Full Text] [Related]
60. A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention.
Nowakowski A; Arbyn M; Turkot MH; Wieszczy P; Miłosz K; Kamiński MF; Didkowska J; Bidziński M; Olszewski W; Wielgoś M; Krzakowski M; Kuchar E; Walewski J
Eur J Cancer Prev; 2020 Mar; 29(2):157-164. PubMed ID: 31517672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
